Kite, A Gilead Company

This study tested a treatment called axicabtagene ciloleucel, which uses a patient's own immune cells that are modified in a lab to attack cancer. It involved 159 adults with follicular or marginal zone lymphoma that had not responded to at least two prior treatments. The main go…

This study tested a new treatment called KTE-X19 (a type of CAR T-cell therapy) in 95 people with mantle cell lymphoma that had come back or stopped responding to other treatments. The goal was to see how many patients had their tumors shrink or disappear. This is not a cure, as …